Pharmacoeconomic Analysis of Ampicillin‐Sulbactam versus Cefoxitin in the Treatment of Intraabdominal Infections

Abstract

We conducted a retrospective pharmacoeconomic analysis of a prospective, multicenter, double‐blind, randomized, controlled trial comparing the β‐lactamase inhibitor combination ampicillin‐sulbactam (96 patients) and the cephalosporin cefoxitin (101) in the treatment of intraabdominal infections. An institutional perspective was adopted for the analysis. The primary outcomes of interest were cure and failure rates, development of new infection, and antibiotic‐related adverse events. Epidemiologic data pertaining to outcomes was retrieved primarily from the trial, although results of other published studies were taken into consideration through extensive sensitivity analyses. Data pertaining to potential resource use and economic impact were retrieved mainly from the University Health Consortium and hospital‐specific sources. When considering only costs associated with drug acquisition through cost‐minimization analysis, a potential savings of $37.24/patient may be realized with ampicillin‐sulbactam relative to cefoxitin based on an average 7‐day regimen. Outcome data collected for the entire hospitalization during the trial revealed an approximately 9% greater frequency of failure with cefoxitin relative to ampicillin‐sulbactam. When considering all outcomes of interest in the initial base‐case analysis, a potential cost savings of approximately $890/patient may be realized with ampicillin‐sulbactam relative to cefoxitin. In assessing the impact of the significant variability in probability and cost estimates, Monte Carlo analysis revealed a savings of $425/patient for ampicillin‐sulbactam over cefoxitin (95% CI $618–1516). Given the model assumptions, our analysis suggests a 78% certainty level that savings will be experienced when ampicillin‐sulbactam is chosen over cefoxitin.